Immunogenicity and reactogenicity of trivalent virosomal influenza vaccine Invivac (Rm) [influenza virus vaccine liposomal] for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: Adults and elderly.

Trial Profile

Immunogenicity and reactogenicity of trivalent virosomal influenza vaccine Invivac (Rm) [influenza virus vaccine liposomal] for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: Adults and elderly.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Influenza virus vaccine liposomal (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 13 Feb 2010 Status changed from suspended to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 14 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top